keyword
MENU ▼
Read by QxMD icon Read
search

eutos score in CML

keyword
https://www.readbyqxmd.com/read/27899952/prognostic-and-predictive-implications-of-sokal-euro-and-eutos-scores-in-chronic-myeloid-leukaemia-in-the-imatinib-era-experience-from-a-tertiary-oncology-centre-in-southern-india
#1
Lakshmaiah Chinnagiriyappa Kuntegowdanahalli, Govind Babu Kanakasetty, Aditi Harsh Thanky, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Rajeev Krishnappa Lakkavalli, Lokesh N Kadabur, Rudresha Antapura Haleshappa
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder. Over the years many prognostic models have been developed to better risk stratify this disease at baseline. Sokal, Euro, and EUTOS scores were developed in varied populations initially receiving various therapies. Here we try to identify their predictive and prognostic implication in a larger population of Indian patients with CML-CP (chronic phase) in the imatinib era.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27818567/the-hasford-score-may-predict-molecular-response-in-chronic-myeloid-leukemia-patients-a-single-institution-experience
#2
Jarosław Dybko, Bożena Jaźwiec, Olga Haus, Donata Urbaniak-Kujda, Katarzyna Kapelko-Słowik, Tomasz Wróbel, Tomasz Lonc, Mateusz Sawicki, Ewa Mędraś, Agnieszka Kaczmar-Dybko, Kazimierz Kuliczkowski
The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score...
2016: Disease Markers
https://www.readbyqxmd.com/read/27751981/changing-treatment-may-affect-the-predictive-ability-of-european-treatment-outcome-study-scoring-on-the-prognosis-of-patients-with-chronic-myeloid-leukemia
#3
Jing Huang, Leyan Wang, Chen Lu, Qun He, Yajing Xu, Fangping Chen, Xielan Zhao
OBJECTIVE: Previous studies compared the predictive ability of European Treatment Outcome Study (EUTOS), Sokal, and Hasford scoring systems and demonstrated inconsistent findings with unknown reason. This study is to determine a useful scoring system to predict the prognosis of patients with chronic myeloid leukemia (CML) and identify the probable factors that affect the scoring. MATERIALS AND METHODS: This is a retrospective cohort study. The predictive ability of EUTOS and the factors that affect scoring were analyzed in 234 Chinese CML-CP patients treated with front-line imatinib, including few patients temporarily administered hydroxyurea for cytoreduction before imatinib...
October 18, 2016: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/27600007/-efficacy-of-three-prognostic-scoring-systems-on-evaluating-the-prognosis-for-patients-with-chronic-myeloid-leukemia
#4
Jing Huang, Xielan Zhao
OBJECTIVE: To retrospectively analyze the efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia (CML) in chronic phase (CP).
 METHODS: In this retrospective cohort study, we collected 234 patients with CML in CP, who were treated with imatinib mesylate (IM). Patients were stratified into low-, intermediate- and high- risk groups according to three scoring systems (Sokal, Hasford and EUTOS), respectively...
August 2016: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/27568522/treatment-and-outcome-of-2904-cml-patients-from-the-eutos-population-based-registry
#5
V S Hoffmann, M Baccarani, J Hasford, F Castagnetti, F Di Raimondo, L F Casado, A Turkina, D Zackova, G Ossenkoppele, A Zaritskey, M Höglund, B Simonsson, K Indrak, Z Sninska, T Sacha, R Clark, A Bogdanovic, A Hellmann, L Griskevicius, G Schubert-Fritschle, D Sertic, J Guilhot, S Lejniece, I Zupan, S Burgstaller, P Koskenvesa, H Everaus, P Costeas, D Lindoerfer, G Rosti, S Saussele, A Hochhaus, R Hehlmann
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (CML) in 20 predefined countries and regions of Europe. Registration time ranged from 12 to 60 months between January 2008 and December 2013. Median age was 55 years and median observation time was 29 months. Eighty percent of patients were treated first line with imatinib, and 17% with a second-generation tyrosine kinase inhibitor, mostly according to European LeukemiaNet recommendations...
September 23, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27428357/advanced-phase-chronic-myeloid-leukaemia-cml-in-the-tyrosine-kinase-inhibitor-era-a-report-from-the-swedish-cml-register
#6
Stina Söderlund, Torsten Dahlén, Fredrik Sandin, Ulla Olsson-Strömberg, Maria Creignou, Arta Dreimane, Anna Lübking, Berit Markevärn, Anders Själander, Hans Wadenvik, Leif Stenke, Johan Richter, Martin Höglund
OBJECTIVES: The primary goal in management of chronic phase (CP) chronic myeloid leukaemia (CML) is to prevent disease progression to accelerated phase (AP) or blast crisis (BC). We have evaluated progression rates in a decentralised healthcare setting and characterised patients progressing to AP/BC on TKI treatment. METHODS: Using data from the Swedish CML register, we identified CP-CML patients diagnosed 2007-2011 who progressed to AP/BC within 2 yrs from diagnosis (n = 18) as well as patients diagnosed in advanced phase during 2007-2012 (n = 36) from a total of 544 newly diagnosed CML cases...
July 18, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27061504/chronic-myeloid-leukaemia-in-spain-its-presentation-characteristics-have-changed-spanish-section-of-the-eutos-population-based-registry
#7
S Osorio, L F Casado, P Giraldo, B Maestro, M Andrade, S Redondo, V García-Gutiérrez, R Ayala, N Garcia, J L Steegmann
OBJECTIVES: To provide more reliable data on the epidemiology of chronic myeloid leukaemia (CML) in Spain than are currently available. MATERIAL AND METHODS: The EUTOS population-based project of European LeukemiaNet is a population registry of new CML cases in patients 18 years of age or older from 22 European areas. The Spanish section included the autonomous communities of Madrid, Castilla-La Mancha and Aragon, from 1-2-2010 to 31-12-2012. RESULTS: A total of 250 cases were recorded in 35 months...
August 2016: Revista Clínica Española
https://www.readbyqxmd.com/read/26925685/significance-of-atm-gene-polymorphisms-in-chronic-myeloid-leukemia-a-case-control-study-from-india
#8
Manjula Gorre, Prajitha Edathara Mohandas, Sailaja Kagita, Anuradha Cingeetham, Sugunakar Vuree, Sarika Jarjapu, Santhoshirani Nanchari, Phanni Bhushann Meka, Sandhya Annamaneni, Nageswara Rao Dunna, Raghunadharao Digumarti, Vishnupriya Satti
BACKGROUND: Development of chronic myeloid leukemia (CML) involves formation of double strand breaks (DSBs) which are initially sensed by the ataxia telangiectasia mutated (ATM) signal kinase to induce a DNA damage response (DDR). Mutations or single nucleotide polymorphisms in ATM gene are known to influence the signaling capacity resulting in susceptibility to certain genetic diseases such as cancers. MATERIALS AND METHODS: In the present study, we have analyzed -5144A>T (rs228589) and C4138T (rs3092856) polymorphisms of theATM gene through polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) in 925 subjects (476 CML cases and 449 controls)...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/26643920/dasatinib-first-line-multicentric-italian-experience-outside-clinical-trials
#9
MULTICENTER STUDY
Massimo Breccia, Fabio Stagno, Luigiana Luciano, Elisabetta Abruzzese, Mario Annunziata, Mariella D'Adda, Alessandro Maggi, Nicola Sgherza, Antonella Russo-Rossi, Patrizia Pregno, Fausto Castagnetti, Alessandra Iurlo, Roberto Latagliata, Michele Cedrone, Nicola Di Renzo, Federica Sorà, Giovanna Rege-Cambrin, Giorgio La Nasa, Anna Rita Scortechini, Giovanna Greco, Luca Franceschini, Simona Sica, Monica Bocchia, Monica Crugnola, Esther Orlandi, Attilio Guarini, Giorgina Specchia, Gianantonio Rosti, Giuseppe Saglio, Giuliana Alimena
Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treatment outside clinical trials. One hundred and nine patients (median age 54 years) were treated from January 2012 to December 2013. Increased incidence of high risk patients were detected according to stratification (26% according to Sokal score, 19% according to Euro score and 16% according to EUTOS) when compared to company sponsored studies...
January 2016: Leukemia Research
https://www.readbyqxmd.com/read/26416462/prognosis-of-long-term-survival-considering-disease-specific-death-in-patients-with-chronic-myeloid-leukemia
#10
M Pfirrmann, M Baccarani, S Saussele, J Guilhot, F Cervantes, G Ossenkoppele, V S Hoffmann, F Castagnetti, J Hasford, R Hehlmann, B Simonsson
In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to CML. This work tackled the reassessment of prognosis under particular consideration of the probabilities of dying of CML. Analyses were based on 2290 patients with chronic phase CML treated with imatinib in six clinical trials. 'Death due to CML' was defined by death after disease progression. At 8 years, OS was 89%. Of 208 deceased patients, 44% died of CML...
January 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/26392775/comparison-of-the-utility-and-applicability-of-the-sokal-hasford-and-eutos-scores-in-a-population-of-chinese-patients-with-chronic-phase-chronic-myeloid-leukemia-undergoing-imatinib-therapy
#11
Leiming Xia, Wei Qian, Mingzhen Yang, Qingsheng Li, Fei Liu, Yanyan Xie
BACKGROUND: Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure. AIM: To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-month and 12-month CCyR, event-free survival (EFS) and progression-free survival (PFS) in patients with chronic-phase CML (CP-CML) undergoing imatinib therapy. METHODS: We retrospectively analyzed the outcome of 210 patients with CP-CML treated at the First Affiliated Hospital of Anhui Medical University treated between January 2006 and December 2013...
2015: OncoTargets and Therapy
https://www.readbyqxmd.com/read/26187695/unfavorable-outcome-of-chronic-myelogenous-leukemia-in-adolescent-and-young-adults-treated-with-tyrosine-kinase-inhibitors
#12
Masatoshi Sakurai, Takehiko Mori, Daiki Karigane, Keiichi Tozawa, Eri Matsuki, Takayuki Shimizu, Kenji Yokoyama, Hideaki Nakajima, Yoshinobu Kanda, Shinichiro Okamoto
Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the outcome of chronic myelogenous leukemia in the chronic phase (CML-CP). However, one study has reported a less favorable treatment outcome with TKIs in adolescents and young adults (AYA) when compared with older patients. In the present study, we retrospectively reviewed the response to TKIs in a Japanese population of 133 CML-CP patients divided into an AYA group (n = 19) and an older group (n = 114). At diagnosis, AYA patients presented with higher white blood cell counts and lower percentage of basophils, and with lower Hasford scores, but no difference was observed in EUTOS score...
September 2015: International Journal of Hematology
https://www.readbyqxmd.com/read/26143137/influence-of-sokal-hasford-eutos-scores-and-pharmacogenetic-factors-on-the-complete-cytogenetic-response-at-1-year-in-chronic-myeloid-leukemia-patients-treated-with-imatinib
#13
Jose Francis, Biswajit Dubashi, Rajan Sundaram, Suresh Chandra Pradhan, Adithan Chandrasekaran
Imatinib mesylate is currently considered the first-line treatment for chronic myeloid leukemia (CML). Sokal, Hasford and EUTOS are the three major risk categorization scores available for CML patients. The present study aimed to explore the influence of three risk score, genetic polymorphisms of ABCB1, OCT1, ABCG2 and trough level concentration on complete cytogenetic response at 1 year and overall survival. The mean time period of follow-up was 53.05 months, and the overall survival was 94.6%. The Sokal score (P 0...
August 2015: Medical Oncology
https://www.readbyqxmd.com/read/25920395/correlation-of-c-ebp%C3%AE-expression-with-response-and-resistance-to-imatinib-in-chronic-myeloid-leukaemia
#14
Sailaja Kagita, Srihari Uppalapati, Sadasivudu Gundeti, Raghunadharao Digumarti
OBJECTIVE: Altered differentiation is a common feature of haematopoietic malignancies with poor prognosis. CAAT/enhancer binding protein alpha (C/EBPα) is a key transcription factor that regulates myeloid differentiation. This study is aimed to know the prognostic value of CAAT/enhancer binding protein alpha expression and correlate its expression with response to imatinib therapy. METHODS: We quantified the expression of C/EBPα gene in 126 chronic myeloid leukaemia samples (82 from newly diagnosed and 44 from imatinib-resistant patients) and 20 control samples...
August 2015: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/25894600/can-prognostic-scoring-systems-for-chronic-myeloid-leukemia-as-established-in-adults-be-applied-to-pediatric-patients
#15
David Gurrea Salas, Ingmar Glauche, Josephine T Tauer, Christian Thiede, Meinolf Suttorp
In contrast to adult medicine, specific scoring systems predicting the treatment response for an individual pediatric patient (pt) with chronic myeloid leukemia (CML) have not yet been defined. We evaluated to what extend prognostic scores as described for adults (e.g., Sokal, Hasford, EUTOS score) resulted in comparable risk group categorizations in a pediatric cohort. Parameters for score calculation were extracted from a data set of 90 patients enrolled into trial CML-PAED-II and treated by a standard dose of imatinib...
August 2015: Annals of Hematology
https://www.readbyqxmd.com/read/25814087/prognostic-scores-for-patients-with-chronic-myeloid-leukemia-under-particular-consideration-of-competing-causes-of-death
#16
REVIEW
Markus Pfirrmann, Michael Lauseker, Verena S Hoffmann, Joerg Hasford
Nowadays in many fields of medicine, prognostic scores are used to predict the outcome for individual patients. In chronic myeloid leukemia (CML), the Sokal, the Euro, and the EUTOS score are established prognostic scores which were addressed by the CML management recommendations of the European LeukemiaNet. This review provides a general definition of prognostic scores and explains their meaning. Main differences between the Sokal, the Euro, and the EUTOS score are highlighted. Due to the therapeutic success of tyrosine kinase inhibitors, the proportion of patients with causes of death unrelated to CML is growing...
April 2015: Annals of Hematology
https://www.readbyqxmd.com/read/25783795/the-eutos-population-based-registry-incidence-and-clinical-characteristics-of-2904-cml-patients-in-20-european-countries
#17
V S Hoffmann, M Baccarani, J Hasford, D Lindoerfer, S Burgstaller, D Sertic, P Costeas, J Mayer, K Indrak, H Everaus, P Koskenvesa, J Guilhot, G Schubert-Fritschle, F Castagnetti, F Di Raimondo, S Lejniece, L Griskevicius, N Thielen, T Sacha, A Hellmann, A G Turkina, A Zaritskey, A Bogdanovic, Z Sninska, I Zupan, J-L Steegmann, B Simonsson, R E Clark, A Covelli, G Guidi, R Hehlmann
This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+ CML that occurred in a sample of 92.5 million adults living in 20 European countries, were registered over a median period of 39 months. 94.3% of the 2904 CML patients were diagnosed in chronic phase (CP). Median age was 56 years. 55.5% of patients had comorbidities, mainly cardiovascular (41...
June 2015: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/25652737/laboratory-recommendations-for-scoring-deep-molecular-responses-following-treatment-for-chronic-myeloid-leukemia
#18
REVIEW
N C P Cross, H E White, D Colomer, H Ehrencrona, L Foroni, E Gottardi, T Lange, T Lion, K Machova Polakova, S Dulucq, G Martinelli, E Oppliger Leibundgut, N Pallisgaard, G Barbany, T Sacha, R Talmaci, B Izzo, G Saglio, F Pane, M C Müller, A Hochhaus
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity...
May 2015: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/25628944/serum-tryptase-at-diagnosis-a-novel-biomarker-improving-prognostication-in-ph-cml
#19
Wolfgang R Sperr, Thomas Pfeiffer, Gregor Hoermann, Susanne Herndlhofer, Christian Sillaber, Christine Mannhalter, Michael Kundi, Peter Valent
Basophilia is an established prognostic variable in Ph-chromosome+ chronic myeloid leukemia (CML). However, in CML, basophils are often immature and thus escape microscopic quantification. We have previously shown that tryptase is produced and secreted by immature CML basophils. In the current study, serum samples of 79 CML patients (chronic phase=CP, n=69; accelerated/blast phase=AP/BP, n=10) treated with BCR/ABL inhibitors, were analyzed for their tryptase content. Serum-tryptase levels at diagnosis were found to correlate with basophil counts and were higher in AP/BP patients (median tryptase: 29...
2015: American Journal of Cancer Research
https://www.readbyqxmd.com/read/25540066/improved-prediction-of-clinical-outcome-in-chronic-myeloid-leukemia
#20
Irena Ćojbašić, Lana Mačukanović-Golubović, Dragan Mihailović, Miodrag Vučić, Stevo Lukić
We sought to develop and compare prognostic models, based on clinical and/or morphometric diagnostic data, to enable better prediction of complete cytogenetic response (CCgR). This prospective longitudinal study included a consecutive series of patients with chronic myeloid leukemia (CML) who were started on imatinib therapy. Logistic regression analysis using backward selection was performed with CCgR at 6, 12, and 18 months as the outcome variables. We evaluated both calibration and discrimination of the model...
February 2015: International Journal of Hematology
keyword
keyword
64426
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"